



Chromatin Repressive Complexes in Stem Cells, Development, and Cancer

Laugesen, Anne; Helin, Kristian

Published in:
Cell Stem Cell

DOI:
[10.1016/j.stem.2014.05.006](https://doi.org/10.1016/j.stem.2014.05.006)

Publication date:
2014

Document version
Peer reviewed version

Citation for published version (APA):
Laugesen, A., & Helin, K. (2014). Chromatin Repressive Complexes in Stem Cells, Development, and Cancer. *Cell Stem Cell*, 14(6), 735-751. <https://doi.org/10.1016/j.stem.2014.05.006>

Chromatin Repressive Complexes in Stem Cells, Development and Cancer

Anne Laugesen¹⁻³ and Kristian Helin¹⁻³

¹Biotech Research and Innovation Centre (BRIC) and ²Centre for Epigenetics, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark. ³The Danish Stem Cell Centre (DanStem), University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark

* Correspondence: kristian.helin@bric.ku.dk

Tel: +45 3532 5666

Fax: +45 3532 5669

Abstract

The chromatin environment is essential for the correct specification and preservation of cell identity through modulation and maintenance of transcription patterns. Many chromatin regulators are required for development, stem cell maintenance and differentiation. Here, we review the roles of the Polycomb repressive complexes, PRC1 and PRC2, and the HDAC1/2-containing complexes, NuRD, Sin3 and CoREST, in stem cells, development and cancer as well as the ongoing efforts to develop therapies targeting these complexes in human cancer. Furthermore, we discuss the role of repressive complexes in modulating thresholds for gene activation and their importance for specification and maintenance of cell fate.

Introduction

The organization of DNA into chromatin is essential for the preservation of genomic integrity in eukaryotic cells and is required for the correct transmission of genetic information over generations. In addition to the physical role of compacting and protecting DNA, the chromatin conformation is closely correlated with the expression state of the genes within its structure. Genes present in a dense chromatin environment are less available to the transcriptional machinery and transcribed to a lesser extent than genes found in looser, and more permissive, chromatin domains. Chromatin is subject to highly dynamic modifications, playing important roles in regulating the availability of DNA and thus gene expression. This regulation includes the exchange of histone variants, nucleosome remodeling by ATP-dependent remodeling complexes as well as posttranslational modifications of DNA and histones (Kouzarides, 2007).

Protruding N-terminal tails of the core histones (Luger et al., 1997), as well as the linker histone H1, are subject to a vast array of posttranslational modifications, some of which are associated with the transcriptional state of the underlying gene, while others appear to play roles in chromatin processes such as cell cycle regulation or the DNA damage response. Histone modifications have different biochemical functions: One, they serve as docking sites for proteins containing conserved domains interacting with the modified residues, thus recruiting other factors to relevant genomic loci. Two, charged modifications, such as lysine acetylation neutralizes the positive charge of the histones, leading to decreased binding of the negatively charged DNA strand, thus loosening the chromatin structure and promoting transcriptional activity (Kouzarides, 2007).

The various cells of an adult organism display distinct phenotypes, yet they all rely on the same underlying genome. To establish cell identity, the correct set of genes must be transcribed, while other genes must be kept in a silent state, and this pattern of gene expression must be maintained in the differentiated cell and propagated through cell generations. Since chromatin regulators ensure stable and heritable cell and tissue specific gene expression patterns over subsequent cell generations, they are important for specifying and maintaining cell identity (Orkin and Hochedlinger, 2011).

With chromatin modifiers being important for maintaining cell identity, it is not surprising that their deregulation can have deleterious effects on cell fate and functions. Indeed, many chromatin modifiers are essential for normal development and are often found deregulated in human disease, including cancer. One intriguing prospect of this is that while genetic mutations are irreversible and thus difficult to target clinically, chromatin modifications are reversible and might thus present promising therapeutic targets. In fact, intense research efforts are currently going into developing inhibitors specifically targeting chromatin-associated proteins, some of which are already in clinical trials and others in clinical use (Helin and Dhanak, 2013).

In this review, we discuss the role of chromatin-mediated transcriptional repression with a particular focus on Polycomb Repressive Complexes, PRC1 and PRC2, and the Hdac1/2-containing complexes, Sin3, NuRD and CoREST. We describe their mechanisms of action in stem cells and development as well as their deregulation in cancer and emerging strategies for targeting them therapeutically.

Polycomb Repressive Complexes

The Polycomb group (PcG) proteins were originally identified in *Drosophila*, as transcriptional repressors required for the correct spatiotemporal expression of developmental regulators along the body axis and mutant flies develop abnormally with homeotic transformations. The PcG proteins assemble into large multi-protein complexes, the best-characterized being PRC1 and PRC2 (Figure 1). PRC1 homologs have been identified in metazoan species from flies to mammals, while the PRC2 homologs are also found in plants and nematodes (Margueron and Reinberg, 2011).

PRC1

Drosophila PRC1 consists of Pc (Polycomb, a chromodomain-containing protein with affinity for H3K27me3), dRing (catalyzing H2A ubiquitylation), Psc (Posterior sex combs, involved in chromatin compaction) and Ph (Polyhomeotic). Mammalian genomes encode several homologs of each of the *Drosophila* PRC1 components with five CBX homologs (CBX2/4/6/7/8), two ubiquitin ligases (RING1A/B), six PCGF family members (PCGF1-6, homologous to Psc) and three PHC family members (Ph homologs). In mammalian cells, PRC1 catalyzes H2AK119 ubiquitylation (H2AK119ub1) and promotes chromatin compaction (Di Croce and Helin, 2013).

PRC2

Mammalian PRC2 contains the core components EZH2 or its closely related homolog EZH1 (homologs of *Drosophila* E(z)), EED (homolog of Esc) and SUZ12 (homolog of Su(z)12), all three of which are required for catalytic activity *in vitro*, while association with the histone chaperone RBBP4/7 seems to be required for catalytic activity *in vivo*. The EZH component contains a SET domain, which catalyzes the methylation of lysine 27 of histone H3 (Margueron and Reinberg, 2011).

Transcriptional Repression by PRCs

Whereas H3K27 is the essential physiological substrate for PRC2 (Pengelly et al., 2013), the precise functional importance of PRC-mediated histone marks remains unclear. The functional role of H3K27me3 has primarily been studied as a recruitment mechanism for CBX-containing PRC1 complexes, and, in *Drosophila*, the catalytic activity of E(z) is required for target gene repression (Muller et al., 2002), while H2AK119ub1 is believed to promote chromatin compaction and transcriptional repression. *In vitro* data shows that PRCs promote condensation of nucleosomal arrays (Francis et al., 2004) and PRC-binding in *Drosophila* mediates chromatin compaction and organization into functional domains, called PcG bodies, as well as long-range interactions important for higher-order chromatin organization (Bantignies et al., 2011; Sexton et al., 2012). Recently, the E3 ligase activity of the Ring1 component of PRC1 was shown to be dispensable for recruitment to and compaction of chromatin at the *Hox* loci in mESCs (Endoh et al., 2012). However, the catalytic activity was indispensable for target gene repression, indicating that H2A ubiquitylation and chromatin condensation represent two separate mechanisms of PRC1-mediated repression (Endoh et al., 2012). Alternative roles of H2AK119ub1 in PRC-mediated repression include prevention of H3K4me3 deposition, inhibition of RNA polymerase II activity and prevention of H2A-H2B dimer eviction from transcribed regions (Di Croce and Helin, 2013).

Recruitment of Polycomb Repressive Complexes

In *Drosophila*, PcG proteins are recruited to DNA stretches termed Polycomb Response Elements (PREs). A distinct PRE for mammalian cells remains elusive, but mammalian PRCs bind CpG rich

promoters of their target genes (Ku et al., 2008), and CpG rich sequences have been shown to mediate PRC2 recruitment (Mendenhall et al., 2010). Several different recruitment mechanisms for PRC2 have been suggested, including association with near-stoichiometric interaction partners (such as PCL1-3, AEBP2, JARID2), association with transcription factors and recruitment by ncRNA (Di Croce and Helin, 2013). The WD40 domains of the RBBP4/7 subunit confer general histone-binding activity to PRC2, while those of EED specifically interact with H3K27me₃, thus providing a potential mechanism for spreading and propagation of the mark. In addition, JARID2 and AEBP2 have both been shown to confer weak CpG-rich DNA-binding activity to the complex, while the Tudor domains of PCL1-3 were recently shown to bind H3K36me_{2/3} (Di Croce and Helin, 2013). The involvement of ncRNAs in PRC recruitment has been most extensively studied in the context of X chromosome inactivation. The accumulation of H3K27me₃ on the inactive X chromosome is dependent on XIST expression, and the A repeats of XIST has been shown to bind PRC2 (Zhao et al., 2008). However, XIST lacking the A repeats is capable of recruiting PRC2, indicating the involvement of other domains of XIST in PRC2 recruitment (Kohlmaier et al., 2004). While a number of studies show association of ncRNAs with PRC2 members, the reports differ in the types of RNAs identified, specific binding areas of the RNAs as well as the PRC2 component involved in the interaction, and the exact role of ncRNAs in PRC2 recruitment remains unclear (da Rocha et al., 2014; Davidovich et al., 2013; Kaneko et al., 2014; Zhao et al., 2010).

Several lines of evidence obtained in *Drosophila* and mammalian cells have shown that PRC1 recruitment to target sites is dependent on PRC2 and H3K27me₃. However, recent studies in PRC2 knockout mESCs have shown only a minor decrease in H2AK119ub1 levels despite a global loss of H3K27me₃ (Leeb et al., 2010). An explanation for this observation has been provided by the characterization of PRC2-independent RING1-containing complexes without any CBX component, which rely on their complex partners RYBP/YAF2 and L3MBTL2 as well as the association with DNA binding proteins such as KDM2B for their recruitment to CpG rich promoters (Farcas et al., 2012; Gao et al., 2012; Qin et al., 2012; Tavares et al., 2012; Wu et al., 2013). Similar to what has been shown in *Drosophila* (Lagarou et al., 2008), the mammalian KDM2B-RING1B complex appears to have higher catalytic activity towards H2AK119ub1 than PRC1.

Accompanying the changes in transcriptional programs during differentiation, PRC binding changes dynamically (Bracken et al., 2006; Mohn et al., 2008). Whether the patterns of PRC binding in various cell types depend on differential expression of interaction partners or ncRNAs, or if PRC binding differs simply as a consequence of differential gene expression patterns and recruitment to untranscribed genes is still unclear. Elucidating the mechanisms regulating PRC binding to target genes is essential for our understanding of the nature of PRC-mediated transcriptional repression.

HDAC1/2-Containing Complexes

HDAC1 and HDAC2 are highly homologous class I histone deacetylases found in large multimeric complexes, the most extensively studied being Sin3, NuRD and CoREST (Figure 2), which are found in species from yeast to human. In addition to the HDAC1/2 catalytic core and RBBP4/7 that are shared among the complexes, they incorporate different subunits, thus providing target specificity or additional catalytic activities. Importantly, many of the subunits have several homologs, allowing for combinatorial assembly of specific complexes with context dependent functions (Kelly and Cowley, 2013).

SIN3

Mammalian genomes encode two homologs of SIN3 (SIN3A/B), which associate individually with HDAC1/2, RBBP4/7, SDS3 and the SIN3-associated proteins SAP18 and SAP30 to form the core SIN3 complex. Different studies have identified additional interaction partners including MeCP2 (methyl-CpG-binding protein), RBP1 (RB-binding protein), BRMS1 (breast cancer metastasis suppressor), ING1/2 (inhibitor of growth), SAP25, SAP130 and SAP180 as well as the histone demethylase RBP2/KDM5A (Hayakawa and Nakayama, 2011; Kadamb et al., 2013).

NuRD

The NuRD (Nucleosome Remodeling Deacetylase) complex couples two important chromatin-modifying activities, namely nucleosome remodeling through the ATP-dependent CHD3/4 helicase subunit and histone deacetylation catalyzed by HDAC1/2. Additional components include the scaffolding proteins GATAD2A/B, conferring histone-binding properties to the complex, while the MBD2/3 and MTA1/2/3 subunits mediate binding to DNA and transcription factors, respectively (Hayakawa and Nakayama, 2011; Lai and Wade, 2011). Some results have suggested that NuRD interacts with the histone demethylase LSD1/KDM1A, potentially adding yet another catalytic activity to its repertoire (Wang et al., 2009b). However, this association is not observed in other purifications, possibly reflecting context specific interactions.

CoREST

Originally described as co-repressor of REST (RE1-silencing transcription factor), CoREST was subsequently found in complex with HDAC1/2 and RBBP4/7 (although not retrieved in some purifications) with additional subunits including Sox-like protein, ZNF217, BHC80 and the histone demethylase LSD1 (Hayakawa and Nakayama, 2011). LSD1 has catalytic activity towards H3K9me1/2 and H3K4me1/2 (Metzger et al., 2005; Shi et al., 2004). However, in the context of CoREST, LSD1 seems to preferentially target H3K4me1/2, while primarily exerting its function as a H3K9 demethylase when associated with nuclear receptors (Kooistra and Helin, 2012).

Transcriptional regulation by HDAC1/2-Containing Complexes

SIN3, NuRD and CoREST are all large, multimeric complexes that serve as scaffolds for assembling different catalytic activities at relevant genomic loci. For NuRD, the CHD3/4 helicase activity has been shown to promote deacetylase activity, possibly by promoting the accessibility of the nucleosome substrate through ATP-dependent nucleosome sliding (Xue et al., 1998). It is note-worthy that all three complexes combine their core deacetylase activity with demethylase interaction partners. For CoREST, the two catalytic activities appear to be interdependent with deacetylation promoting demethylation (Lee et al., 2006a), pointing to a functional interplay extending beyond mere co-localization.

In accordance with histone acetylation being associated with transcriptional activation, HDAC-containing complexes reversing this modification are traditionally described as co-repressors promoting transcriptional repression of their target genes. Importantly, however, it has been shown that dynamic acetylation/deacetylation is required for active transcription to occur, thus pointing to important roles of HDAC-containing complexes in activating transcription in addition to their function as co-repressors (Clayton et al., 2006; Kelly and Cowley, 2013). Indeed, ChIP-sequencing studies show

that HDACs also co-localize with acetyltransferases at transcriptionally active loci, presumably acting to reset acetylation levels after gene activation (Wang et al., 2009c). Thus, the transcriptional regulation exerted by HDAC1/2-containing complexes might be highly context dependent.

Recruitment of HDAC1/2-Containing Complexes

Recruitment of the HDAC1/2-containing complexes seems to rely on cell-type specific transcription factor binding as well as chromatin-binding domains within certain subunits (Hayakawa and Nakayama, 2011). Each of the complexes contain at least two subunits with histone-binding properties such as PHD-fingers, chromodomains and Tudor domains as well as the WD40 repeats of RBBP4/7 (Kelly and Cowley, 2013).

The existence of several homologs for most of the components indicates that specific complex composition might confer distinct binding patterns and influence their biological function in different cell types (Kelly and Cowley, 2013). For instance, NuRD complex containing MBD2 is functionally distinct from MBD3-NuRD (Le Guezennec et al., 2006). MBD2 recruits NuRD to methylated CpGs, while MBD3 is unable to bind methyl-cytosine due to amino acid substitutions in the methyl-binding domain. However, NuRD is recruited to some target genes independently of their methylation status, and the MBD component is thus only partly responsible for NuRD recruitment (Baubec et al., 2013). Similarly, the MTA proteins are incorporated into distinct NuRD complexes with differential transcription factor binding and recruitment to specific genomic loci (Lai and Wade, 2011).

Thus, for PRCs as well as HDAC1/2-containing complexes, it seems that specific subunit composition and association with cell-type specific interaction partners is important for regulating their recruitment and biological function.

Chromatin Repressive Complexes in Pluripotent Stem Cells

ESCs display an open and permissive chromatin structure with low levels of DNA methylation and a greater abundance of activating histone modifications, such as H3K4me3 and histone acetylation. In addition, structural proteins such as heterochromatin protein 1 (HP1), the linker histone H1 and the core histones display highly dynamic kinetics in their association with chromatin in ESCs, further opening the chromatin structure (Azura et al., 2006; Meshorer et al., 2006). The hyperdynamic nature of ESC chromatin correlates with a very high level of transcriptional activity and a high abundance of general transcription factors and chromatin modifiers (Efroni et al., 2008), central to maintaining transcriptional patterns in the open chromatin structure. Upon differentiation, the overall chromatin structure shifts towards a tighter, more restrictive configuration with decreased transcriptional activity and concomitant accumulation of H3K27me3 (Zhu et al., 2013) as well as induction of large H3K9me3-positive heterochromatic foci (Meshorer et al., 2006).

Chromatin regulators along with tightly regulated transcription factor circuits play important roles in balancing self-renewal and pluripotency in ESCs, and the open chromatin environment appears to be important for the maintenance of pluripotency. Conversely, the open, permissive chromatin environment necessitates the action of chromatin repressive complexes in order to protect against inappropriate transcription of differentiation factors as well as for the orchestration of differentiation through the timely repression of pluripotency-associated genes (Orkin and Hochedlinger, 2011).

Polycomb Repressive Complexes in Embryonic Stem Cells

PRCs are highly expressed in ESCs and have been shown to bind CpG-rich promoters of genes for transcription factors and signaling molecules controlling development (Boyer et al., 2006; Bracken et al., 2006; Lee et al., 2006b). In addition, PcG proteins and their marks are found at some repetitive elements and involved in imprinting and X-chromosome inactivation (Casa and Gabellini, 2012).

While the PRC2 components are essential for mouse development, mESCs lacking *Eed*, *Suz12* or *Ezh2* can be derived from knockout embryos, yielding similar phenotypes with retention of self-renewal capacity, loss of H3K27me2/3 and *in vitro* differentiation defects. Consistent with the *in vitro* defects, chimeric embryo complementation studies show that knockout mESCs initiate differentiation, but display abnormal long-term repression of pluripotency factors and lack robust induction of differentiation factors (Chamberlain et al., 2008; Montgomery et al., 2005; Pasini et al., 2007; Shen et al., 2008). Notably, the passage number of *Eed*^{-/-} cells influences the phenotype: high-passage *Eed*^{-/-} cells display more pronounced derepression of target genes and a global loss H3K27me1, while the phenotype of low-passage *Eed*^{-/-} cells appears identical to those of *Ezh2*^{-/-} and *Suz12*^{-/-} cells (Chamberlain et al., 2008).

Ring1b-deficient mESCs have reduced levels of H2AK119ub1, a slight deregulation of some target genes and a loss of differentiation potential (Leeb and Wutz, 2007), while *Ring1a/Ring1b* double knockout mESCs lose the ability to self-renew after a few passages and show defects in cell cycle regulation, pointing to PRC2-independent roles of Ring1a/Ring1b (Endoh et al., 2008). Knockdown studies show that the non-canonical PRC1 components Rybp or Kdm2/Fbxl10 are dispensable for self-renewal, while loss of either factor diminishes H2AK119ub1 levels and compromises the *in vitro* differentiation potential (Gao et al., 2012; Wu et al., 2013). Recently, different Cbx subunits of PRC1 were shown to have specific roles with Cbx7 being required for maintaining the pluripotent state of mESCs, with a shift in composition to Cbx2/4 being important during differentiation (Morey et al., 2012).

HDAC1/2-Containing Complexes in Embryonic Stem Cells

Hdac1 and Hdac2 are both dispensable for mESC self-renewal, but while *Hdac2*^{-/-} cells retain their *in vitro* differentiation potential, *Hdac1* knockout disrupts normal differentiation (Dovey et al., 2010). Several NuRD subunits have been shown to interact with core pluripotency factors, including Oct4 and Nanog, forming the NODE complex (Nanog- and Oct4-associated deacetylase) (Liang et al., 2008), which might be functionally distinct from Mbd3-containing NuRD. While the relative contributions of different Hdac1/2-containing complexes remain unclear, several studies show important roles of subunits of each of these complexes in mESCs.

In vitro culture of *Sin3a*^{-/-} blastocysts yield smaller colonies and insufficient outgrowth of the ICM, showing important roles of Sin3a in the establishment of mESCs (Cowley et al., 2005), and consistent with the peri-implantation lethality observed for *Sin3a*^{-/-} mice. Mbd3-deficient mESCs can be derived and propagated in culture, but display defects during differentiation (Kaji et al., 2006; Rais et al., 2013). Knocking out *Lsd1* in mESCs leads to reduced CoREST levels, a slight deregulation of gene expression and defects during embryoid body formation with incomplete silencing of pluripotency-associated genes (Foster et al., 2010; Wang et al., 2009a). Lsd1 has also been shown to co-localize

with NuRD at the enhancers of pluripotency-associated genes, where it is required for the downregulation of H3K4me1-levels during differentiation (Whyte et al., 2012).

Chromatin Repressive Complexes and Pluripotency

Many repressive complexes do not seem to be essential for the self-renewal of ESCs, while both *in vivo* and *in vitro* data demonstrate their requirement for pluripotency. It has been suggested that one of the key functions of chromatin regulation is in noise reduction, meaning that the presence of nucleosomes and other chromatin-bound factors act to limit the propensity of promiscuous transcriptional activity such that several cues need to act in concert in order for transcription to take place. Studies from yeast support this theory: By competing with transcription factors and the transcriptional machinery for access to promoters, chromatin acts to increase the threshold for gene activation and limit transcriptional noise (Lam et al., 2008), see also e.g. (Chi and Bernstein, 2009). This view might help explain the phenotype of ESCs lacking chromatin repressive complexes: As long as cells are grown in defined media, loss of a complex does not lead to widespread gene activation or changes in cell identity. However, it might lower the threshold for gene activation giving rise to transcriptional noise. Thus, during differentiation in an environment with multiple signals and different types of cells, the more relaxed chromatin makes cells lacking repressive complexes more susceptible to aberrant activation of gene expression, which can result in differentiation and developmental failures. The normal role of the repressive chromatin complexes is therefore to ensure that sustained and strong signals are required for changing the transcription program and the specification of differentiation. The importance of defined media in this context is illustrated by the early observations that knockout of e.g. *Ezh2* or *Mbd3* was incompatible with the establishment of pluripotency (Kaji et al., 2007; O'Carroll et al., 2001). Both observations have since been refuted by the establishment of knockout mESCs lacking either factor, most likely through the refinement of experimental procedures or the introduction of optimized culture conditions such as 2i/LIF (Rais et al., 2013; Shen et al., 2008).

In the context of pluripotent cells, a much-debated feature is the observation of bivalent domains in the promoters of developmental genes, defined by the presence of H3K4me3 alongside H3K27me3 (Azuara et al., 2006; Bernstein et al., 2006). This co-occurrence observed by ChIP-sequencing approaches might represent the two marks existing simultaneously on the same histone tail, on opposite H3 tails of the same nucleosome or on neighboring nucleosomes. In addition, it has been argued that bivalent promoters might simply represent an artifact of heterogeneous cell populations. While additional observations of bivalent domains in the early embryo and differentiated cell types and the application of sequential ChIP and mass spectrometry approaches have shown the existence of truly bivalent promoters, their functional relevance remains unclear. With all CpG rich promoters being H3K4me3-positive in mESCs (Mikkelsen et al., 2007) and PRC2 being recruited to CpG-rich stretches, the co-occurrence of H3K4me3 and H3K27me3 is to be expected. Bivalent genes are found to be transcriptionally inactive, but are generally thought to be poised for activation upon differentiation, thus providing plasticity to the chromatin structure (Voigt et al., 2013). However, recent studies show that loss of H3K4me3 from bivalent promoters does not disrupt the large-scale responsiveness of gene activation upon *all trans*-retinoic acid-induced differentiation of mESCs, thus questioning the prevailing view of the functional relevance of bivalency (Denissov et al., 2014; Hu et al., 2013).

ChIP analyses show binding of the Chd4 component of NuRD at bivalent Polycomb target gene promoters and reveal potential co-regulation of the two complexes with common target genes gaining H3K27ac and losing PRC2 binding as well as H3K27me3 in *Mbd3*^{-/-} cells (Reynolds et al., 2012b). This indicates that NuRD and PRC2 might be functionally linked through occupation of some of the same genomic loci, where NuRD might facilitate PRC2 recruitment and methylation through deacetylation of H3K27. This potential co-regulation is reminiscent of observations in *Drosophila*, where HDAC1/RPD3 collaborates with PcGs in repressing a subset of PcG target genes (Tie et al., 2001).

Interestingly, Hdac1 and Mbd3 have been found to associate with the promoters of many actively transcribed genes, including core pluripotency factors. Importantly, however, comparative analysis of mESCs showed that target gene expression was primarily upregulated upon *Hdac1* knockout, indicating that NuRD acts as a transcriptional repressor even at actively transcribed genes (Kidder and Palmer, 2012). In a recent study, Reynolds et al. investigated the role of NuRD in regulating pluripotency and lineage commitment of mESCs. The authors found that rather than silencing pluripotency-associated genes, NuRD is required to restrict transcript levels below a threshold, thereby sensitizing cells to differentiation cues and facilitating lineage commitment in response to the relevant stimuli (Reynolds et al., 2012a). Thus, NuRD and other repressive complexes might not function as traditional silencers, but rather by fine-tuning expression levels of their target genes (Hu and Wade, 2012; Reynolds et al., 2013).

In the acquisition of pluripotency through reprogramming of somatic cells, the chromatin environment undergoes major reorganization towards an open chromatin structure along with erasure of DNA methylation and redistribution of histone modifications, and many chromatin modifiers appear to influence this process. Cell fusion experiments using mESCs with knockout of PRC1 or PRC2 components show that functional PRCs are required for reprogramming of human B cells (Pereira et al., 2010). Similarly, shRNA-mediated knockdown of PRC1 or PRC2 components impaired the conversion of human fibroblasts to induced pluripotent stem cells (iPSCs) (Onder et al., 2012), while ectopic *Ezh2* or *Bmi1* expression increases the efficiency of iPSC generation (Buganim et al., 2012; Moon et al., 2011). In this context, it is important to keep in mind the differences between mouse and human pluripotent cells. Indeed, *Ezh2* knockout does not impair iPSC formation from MEFs (Fragola et al., 2013), indicating that *Ezh2* is not required for reprogramming of mouse cells. However, the authors note that despite a global loss of H3K27me3 upon *Ezh2* knockout, this mark is retained on a subset of important developmental regulators, most likely deposited by *Ezh1*-PRC2. Indeed, knockdown of *Eed* in the *Ezh2*-deficient cells diminishes the remaining H3K27me3 and prohibits reprogramming (Fragola et al., 2013). Another important aspect to consider is the potentially distinct requirements of repressive complexes during early and late stages of reprogramming (Ho et al., 2013) as well as effects on proliferation, which are not directly linked to the acquisition of pluripotency, yet would still influence reprogramming efficiency.

While the PRCs are observed to positively influence reprogramming, the opposite situation has been reported for other repressive chromatin regulators. Recently, depletion of the core NuRD component *Mbd3* was shown to increase the efficiency of iPSC generation (Luo et al., 2013; Rais et al., 2013). One explanation for the seemingly discrepant roles of these repressor complexes might be that PRCs are primarily involved in repression of differentiation-associated genes, while NuRD also plays

important roles in the regulation of pluripotency-associated genes. In contrast, however, a separate study shows that Mbd3 is required for the establishment of iPSC from mouse neural stem cells as well as the more primed epiblast stem cells and preiPSCs, while ectopic expression of Mbd3 with Nanog promotes reprogramming (dos Santos et al., 2014, *in press*). These discrepancies might stem from differences in the experimental approaches and culture conditions applied, underlining the context-dependent nature of such studies.

Collectively, a plethora of studies demonstrate important roles of chromatin repressive complexes in governing cell identity and guarding the pluripotent state of ESCs. Tables 1 and 2 summarize the observed phenotypes of loss-of-function studies concerning repressive complexes components in pluripotent cells.

Chromatin Repressive Complexes in Tissue Stem Cells and Development

During embryonic development, the chromatin environment is modulated to facilitate specification and maintenance of the various cell types. Accordingly, many components of chromatin repressive complexes are required for normal development. The exact phenotypes vary according to the specific component investigated, but general features include defects in early lineage specification upon knockout of *Ring1b* or core PRC2 members (Faust et al., 1995; O'Carroll et al., 2001; Pasini et al., 2004; Voncken et al., 2003) and several members of HDAC1/2-containing complexes (Cowley et al., 2005; David et al., 2003; Hendrich et al., 2001; Lagger et al., 2002; Wang et al., 2007a) as well as later developmental problems with defects in cell type specification and tissue development as observed for several components. In the context of PRC2, it is noteworthy that *Jarid2* knockout leads to defects in neural tube formation with embryonic lethality around E15.5 (Takeuchi et al., 1995), while *Pcl2* knockout mice display an incompletely penetrant phenotype of skeletal transformation (Wang et al., 2007b), providing evidence that neither interacting protein is solely responsible for PRC2 recruitment.

Interestingly, the existence of multiple homologs of certain components appears to provide some functional redundancy during development. For instance, mice lacking the PRC1 component *Pcgf2/Mel18* or the closely related gene *Pcgf4/Bmi1* are viable with homeotic transformations (Akasaka et al., 1996; van der Lugt et al., 1994), while concomitant deletion of both genes leads to embryonic lethality around E9.5 (Akasaka et al., 2001). In the context of multiple homologs, important factors to consider include spatiotemporal expression patterns as well as potential distinctive functions of the homologous proteins, which can give rise to distinct phenotypes of loss of single homologs. This is exemplified by the fact that knockout of *Ezh2*, *Ring1b*, *Hdac1* or *Sin3a* leads to early embryonic lethality, while the loss of their closely related structural homologs have less severe consequences on development. The observed phenotypes from knockout studies of components of Polycomb group proteins and HDAC1/2-containing complexes are summarized in Tables 1 and 2.

In addition to their roles during early embryonic development, chromatin repressive complexes play important roles in maintaining gene expression patterns and cell identity of many different tissues. The roles of PRCs and HDAC1/2-containing complexes in tissue stem cells and development are discussed below and summarized in Supplementary Tables 1 and 2.

Polycomb Repressive Complexes in Tissue Stem Cells and Development

The PRCs have been most extensively studied in mESCs, but a growing number of studies demonstrate important roles of PRCs in tissue-specific stem and progenitor cells and conditional knockout studies show that the PRCs are required during many aspects of mammalian development.

In the hematopoietic system, Bmi1 is required for self-renewal of hematopoietic stem cells (HSCs) through a mechanism involving the repression of the *Ink4a-Arf* locus (Park et al., 2003), and *Bmi1* knockout promotes premature and deficient lymphocytic specification (Oguro et al., 2010). Interestingly, the specific composition of PRC1 with regards to the Cbx component seems to be important for the transition from self-renewal to differentiation during hematopoiesis. As in mESCs, Cbx7 is required for HSC self-renewal, while Cbx2/4/8-containing PRC1 seems to be important during differentiation (Klauke et al., 2013). In addition, overexpression of Cbx7 or Kdm2b promotes HSC self-renewal and the number of colony-forming cells during serial transplantations (Klauke et al., 2013; Konuma et al., 2011). Studies of PRC2 in the hematopoietic system show that Ezh2 is required for normal lymphopoiesis (Su et al., 2003), and PRC2 is involved in HSC self-renewal with Ezh2 being important for HSC self-renewal during fetal liver hematopoiesis, while Ezh1 maintains the HSC compartment in the adult bone marrow (Hidalgo et al., 2012; Mochizuki-Kashio et al., 2011), once again highlighting the importance of context-specific incorporation of different homologs. Given the many recent reports of increased expression levels and loss-of-function mutations of PRC2 members as well as hyperactive oncogenic EZH2 mutants in hematopoietic cancers, it is highly relevant to further study the role of PRCs in normal and malignant hematopoiesis.

PRCs also contribute the self-renewal capacity of neural stem cells by maintaining the *Ink4a-Arf* locus in a repressed state (Molofsky et al., 2003), and they are involved in the timely repression of neurogenic factors, promoting the neurogenic-to-astrogenic switch (Hirabayashi et al., 2009; Roman-Trufero et al., 2009). Important roles of the PRCs have also been described in epidermal stem cells, skeletal and cardiac muscle, hepatic stem cells and in the skeletal system (Supplementary Table 1).

While many studies have shown the requirement of PRCs for maintaining the differentiation capacity of both mESCs and tissue-specific stem cells, PRC components appear to be specifically required for self-renewal of a wide range of tissue-specific stem cells. The basis for this differential requirement is not entirely clear, but the consideration of several factors could provide some explanation: The use of defined media and culture conditions might influence the outcome of loss-of-function studies, as illustrated by the fact that some of the phenotypes observed in mESCs grown in serum/LIF have been refuted by the introduction of 2i/LIF-based medium yielding more homogenous cell populations influenced by fewer environmental cues. Furthermore, lineage-committed tissue-specific stem cells residing in more complex and heterogeneous environments or grown in less well-defined media outside their niche might be more sensitive to the loss of chromatin factors. During differentiation, the chromatin environment changes to a more restrictive conformation with accumulation of repressive chromatin marks such as H3K27me3 (Zhu et al., 2013). In the context of lineage-committed cells, loss of PRC2 would influence this organization, leading to failures in differentiation and/or altering developmental potential, as illustrated by the enhanced plasticity observed in *Ezh2*-deficient T cells (Tumes et al., 2013).

Hdac1/2-Containing Complexes in Tissue Stem Cells and Development

While Hdac1/2 are considered to act redundantly in most cell types, important exceptions to this view include distinct roles during early embryogenesis, where Hdac1 is essential and required for proliferation through repression of cell cycle inhibitors (Lagger et al., 2002). In addition, conditional knockout studies with combinatorial ablation of *Hdac1/2* demonstrate distinct roles during epidermal development, where loss of a single allele of *Hdac2* in an *Hdac1* knockout background leads to developmental defects (Winter et al., 2013), and the opposite situation in neuronal development, where *Hdac1* haplo-insufficiency is observed in *Hdac2* knockouts (Hagelkruys et al., 2014).

Studies in knockout mice and tissue-specific stem cells show important roles of Hdac1/2-containing complexes in many different tissues, including roles of NuRD, Sin3 and CoREST in the hematopoietic system (Cowley et al., 2005; David et al., 2008; Kerenyi et al., 2013; Williams et al., 2004; Yao et al., 2014; Yoshida et al., 2008; Zhang et al., 2012b), roles of NuRD in epidermal stem cells (Kashiwagi et al., 2007), and roles of REST/CoREST and Lsd1 in neural stem cells and during neural development (Qureshi et al., 2010; Sun et al., 2010; Wang et al., 2007a) (Supplementary Table 2).

Taken together, chromatin repressive complexes are essential for establishing and maintaining cell identity during tissue development and homeostasis, in part through their ability to restrict the expression of important cell cycle regulators and key developmental genes. One emerging picture is that subunit composition and association with specific interactors provide important means for regulating the function of the complexes in different cell types and developmental stages. Further elucidation of the molecular basis of tissue-specific functions of repressor complexes will be crucial for understanding the consequence of their deregulation in cancer.

Chromatin Repressive Complexes in Cancer

Many cancers display a dedifferentiated stem cell-like phenotype, and several of the factors required for establishing or maintaining stem cell states are also involved in oncogenesis. Thus, bearing in mind that chromatin repressors are crucial for establishing and preserving cellular identity, it is to be expected that chromatin repressors would often be found deregulated in human cancers. Intense research is going into elucidating the mechanism by which chromatin modifiers and modifications promote cancer development or progression. One of the early recurring questions in cancer epigenetics was that of “cause or consequence”, that is, whether the chromatin environment is deregulated as a consequence of the cancer or if the chromatin regulators play a direct role in driving oncogenesis. However, recent discoveries of copious numbers of recurrent somatic mutations in genes encoding chromatin-associated proteins argue that a deregulated chromatin environment can play a causal role in the disease (You and Jones, 2012). In the following, we will discuss reports of deregulated chromatin repressors as well as their emerging roles as targets for anti-cancer therapeutics.

Polycomb Repressive Complexes and Cancer

Increased levels of EZH2 have been correlated with poor outcome in metastatic prostate cancer and poor prognosis in tumors of other tissues (Bracken et al., 2003; Kleer et al., 2003; Takawa et al., 2011; Varambally et al., 2002; Wagener et al., 2010). Recently, recurrent point mutations in the SET domain of EZH2 have been described in diffuse large B cell lymphoma and follicular lymphoma, conferring hyperactivity of EZH2 yielding increased levels of H3K27me3 (Beguelin et al., 2013; Lohr et

al., 2012; McCabe et al., 2012a; Morin et al., 2010; Pasqualucci et al., 2011; Ryan et al., 2011). Further evidence for direct roles of H3K27 methylation in cancer includes loss-of-function mutations of the demethylase UTX (Dalglish et al., 2010; van Haaften et al., 2009) and the recent discoveries of somatic mutations of lysine 27 in H3.3 in pediatric glioblastoma (Schwartzentruber et al., 2012; Wu et al., 2012). However, this mutation has been shown to inhibit PRC2 activity, leading to lower H3K27me3 levels. Loss-of-function mutations of EZH2 as well as SUZ12, EED and JARID2 have been identified in myeloid cancers (Ernst et al., 2010; Nikoloski et al., 2010; Puda et al., 2012; Ueda et al., 2012) and T-ALL (Ntziachristos et al., 2012; Simon et al., 2012; Zhang et al., 2012a) as well as cancers of other tissues. Thus, the role of PRC2 in cancer is highly context dependent with EZH2 exerting functions as an oncogene as well as a tumor suppressor.

Indications of PRC1 involvement in human cancer include increased expression levels of BMI1 and correlation with poor prognosis in a range of solid tumors and hematological cancers (He et al., 2009; Mohty et al., 2007; Nowak et al., 2006; Shafaroudi et al., 2008) and reports of oncogenic functions of CBX7 in the hematopoietic system (Klauke et al., 2013; Scott et al., 2007) and some solid tumors (Shinjo et al., 2013; Zhang et al., 2010) as well as tumor suppressor roles in others (Forzati et al., 2012).

HDAC1/2-Containing Complexes and Cancer

While somatic mutations in HDACs are rare, there are many reports of HDAC1/2 being overexpressed in human cancers, often correlating with poor patient outcome. In contrast, there is also data on cancer-associated loss-of-function mutations of HDAC1/2, and knockout mouse models show that these proteins can also exert tumor suppressive roles (West and Johnstone, 2014). In addition, HDACs are aberrantly recruited to target genes in many cancers, in part due to altered expression level of specific subunits of the HDAC-containing complexes. The SIN3-associated protein BRMS1 is often lost in invasive stages of human cancers (Hurst, 2012), and ING1/2 are often mutated or downregulated in human cancers, pointing to tumor suppressive roles of SIN3 (Guerillon et al., 2014). The MTA subunits are the most studied components of NuRD with a role in cancer. As the name implies, MTA1 (metastasis associated gene 1) was originally identified by its preferential expression in a metastatic tumor model, and increased expression in a wide range of tumors correlates with tumor grade and poor prognosis (Nicolson et al., 2003). Interestingly, there is an inverse correlation between MTA1 and MTA3 expression during cancer progression, and MTA3 seems to play mainly tumor suppressive functions, thus pointing to the importance of specific subunit composition in regulating complex function (Lai and Wade, 2011). ZNF217 is overexpressed in cancers and was found to recruit CoREST to the *INK4B* locus (Thillainadesan et al., 2012), thus promoting proliferation, and LSD1 expression is elevated in many human cancers (Helin and Dhanak, 2013), but is also reported to be downregulated and involved in the suppression of metastasis in breast cancers (Wang et al., 2009b). Whether LSD1 exerts its functions in cancer mainly as a subunit of NuRD, CoREST or along with additional factors remains to be elucidated.

Molecular Mechanisms of Chromatin Repressive Complexes in Cancer

The mechanisms by which repressive complexes proteins contribute to oncogenesis include their roles in repressing genes activated by stress signals and involved in proliferation. PcG proteins bind the *INK4A-ARF-INK4B* locus and overexpression of PcG proteins prevents expression of p14 (ARF), p15 (INK4B) and p16 (INK4A) in response to stress signals, including oncogenes (Bracken et al., 2007).

While cancer cells generally display global DNA hypomethylation, CpG islands of tumor suppressor genes are often aberrantly methylated in cancer. Interestingly, PcG binding has been suggested to predispose promoters for DNA hypermethylation (Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007). Oncogenic fusion proteins have been implicated in aberrant targeting of repressive complexes to chromatin, including PLZF-RAR α -mediated recruitment of PRC1 and PML-RAR α -mediated recruitment of PRC2, DNMTs and NuRD in leukemia (Lai and Wade, 2011; Richly et al., 2011). NuRD, LSD1 and PcG proteins have been shown to promote the epithelial-to-mesenchymal transition (EMT) through TWIST- or SNAIL1-mediated downregulation of E-cadherin (Tam and Weinberg, 2013), and EZH2 overexpression seems to promote tumor angiogenesis (Lu et al., 2010). Another important aspect is the role of repressive complexes in governing cell identity: indeed, aberrant expression of PcG proteins helps sustaining a dedifferentiated phenotype as seen for instance in rhabdomyosarcoma, where knockdown studies and application of specific inhibitors targeting EZH2 is able to partially reinstate muscle cell identity to the tumor cells (Marchesi et al., 2012).

Although the involvement of chromatin repressive complexes in cancer is indisputable, their functional role in oncogenesis is still incompletely understood as they promote oncogenesis in one setting, while protecting against malignant transformation in another. This duality is probably related to the role of chromatin modifiers in modulating transcriptional output of target genes with opposing functions. Rather than directly deciding the transcription programs, alterations in the level of chromatin regulators changes the threshold for transcriptional activation or repression and this altered chromatin balance sensitizes the cell to stimuli promoting oncogenic transformation. Deciphering the role of repressive complexes in specific cancer types will be important for furthering our understanding and guiding new therapies.

Targeting Chromatin Repressive Complexes in Cancer

While genetic lesions are difficult to target therapeutically, targeting the deregulated chromatin environment is tempting due to the reversibility of the system. Several drugs targeting chromatin modifiers are already being used in the clinic. Most famously, DNA methyltransferase inhibitors are used to treat patients with MDS, where they prolong life span and prevent the progression to leukemia (Helin and Dhanak, 2013).

HDAC Inhibitors

Another class of molecules already being used in the clinic is HDAC inhibitors, which are currently used in the treatment of T-cell lymphoma. The FDA-approved Vorinostat and Romidepsin target Class I HDACs and are able to inhibit the function of HDAC1/2 in the context of SIN3, NuRD and CoREST (Khan and La Thangue, 2012; West and Johnstone, 2014). The molecular mechanisms of these drugs are still incompletely understood, but treatment outcomes include cell cycle arrest via induction of p21, increased apoptosis, anti-angiogenic effects via HIF1 inhibition as well as sensitization of cancer cells to DNA damaging agents (Khan and La Thangue, 2012). Despite these encouraging results, there is no clear correlation between acetylation levels and clinical outcome upon HDAC inhibition. In addition, it has been difficult to establish robust biomarkers to predict efficacy, and, thus far, these drugs are limited to treatment of specific hematological cancers (Helin and Dhanak, 2013).

LSD1 Inhibitors

In addition to HDAC inhibitors, LSD1 inhibition represents a potential novel route of targeting complexes such as NuRD and CoREST. Two recent studies have provided evidence for an important role of LSD1 in acute myeloid leukemia (Harris et al., 2012; Schenk et al., 2012). Neither study observes any global effect on histone methylation, but both report localized increases in H3K4me2 at specific promoters, including the differentiation marker CD11b (Schenk et al., 2012), and certain MML-AF9 targets (Harris et al., 2012). These studies raise several questions regarding the function of LSD1 in leukemia: First, LSD1 binds throughout the genome as part of several different complexes, yet the effects on H3K4me2 are very localized. Second, while LSD1 inhibition leads to an increase in CD11b expression (Schenk et al., 2012), the increased H3K4me2 at MML-AF9 target genes is actually accompanied by lower expression (Harris et al., 2012), which is surprising considering that H3K4me2 is usually associated with gene expression. Thus, while these studies are encouraging, the mechanisms underlying the differentiation and apoptosis-inducing properties of LSD1 inhibitors remain to be elucidated.

EZH2 Inhibitors

With EZH2 being overexpressed in many cancers and the recent reports on hyperactive EZH2 mutants in follicular lymphoma and diffuse large B-cell lymphoma, specific EZH2 inhibitors are attracting interest as potential anti-cancer drugs. Several highly selective compounds show promising results in reducing H3K27me3 levels, decreasing proliferation and increasing apoptosis in lymphoma cell lines carrying SET domain mutations and markedly reducing tumor burden and increasing survival in mouse xenograft models (Knutson et al., 2014; Knutson et al., 2012; McCabe et al., 2012b; Qi et al., 2012), and two EZH2 inhibitors have entered clinical trials (www.clinicaltrials.gov). Interestingly, EZH2 inhibition has also been shown to inhibit the growth of rhabdoid tumors and lowering intra-tumor levels of H3K27me3, potentially expanding the therapeutic range beyond hematopoietic malignancies (Knutson et al., 2013). These pediatric tumors arise from a loss of the SNF5 component of the SWI/SNF remodeling complex (Versteeg et al., 1998). They display elevated EZH2 levels, and conditional knockout of *Ezh2* has been shown to reduce tumor growth (Wilson et al., 2010). Interestingly, this type of tumor only carries few somatic mutations (Lee et al., 2012), potentially making them more dependent on the chromatin environment and one might speculate that other tumor types with few somatic mutations could show similar vulnerability to PRC2 inhibitors. Importantly, despite clear effects on prohibiting cancer growth, it has not been possible to identify consistent transcriptional profiles being reverted upon treatment with EZH2 inhibitors (McCabe et al., 2012b). This lack of consistency indicates that EZH2 targets different pathways even within the same types of tumors, in agreement with a role of chromatin factors in threshold modulation as opposed to directly deciding the transcriptional outcome. With EZH2 exhibiting characteristics of an oncogene as well as a tumor suppressor even within hematological cancers, it will be important to develop tools and biomarkers to predict efficacy of targeting EZH2 therapeutically and to stratify patients accordingly.

Alternative Ways of Targeting Polycomb Repressive Complexes

In the context of targeting PcG proteins in cancer, several new drugs are currently being tested. One approach, targeting the EED-EZH2 interface by treatment with a stabilized α -helix of EZH2, shows disruption of PRC2 complex formation, lower levels of H3K27me3, growth arrest and differentiation of MLL-AF9 driven leukemic cells (Kim et al., 2013). In the context of targeting PRC1, application of small-molecule BMI1 inhibitors reduced global H2AK119ub1 in colorectal cancer cells and decreased

tumor load in transplanted mice through a depletion of cancer-initiation cells (Kreso et al., 2014). Another potential approach to targeting PRC1 is by chromodomain inhibitors targeting the CBX-component. Recently, Simhadri et al. reported on the development of a chromodomain antagonist with 10-400 fold selectivity for CBX7 over other CBX family members (Simhadri et al., 2014). In addition, studies of BET (bromodomain and extracellular) domain inhibitors targeting BRD4 indicate that targeting domains recognizing histone modifications is therapeutically feasible (Di Croce and Helin, 2013). With its oncogenic roles in the hematopoietic system and CBX7 being preferentially involved in undifferentiated cell types, it will be interesting to explore CBX7 inhibition as a potential novel strategy for targeting PRC1 in cancer.

Concluding Remarks

The chromatin environment is an important factor in the establishment and maintenance of cell identity. Accordingly, the protein complexes modulating chromatin are important for many aspects of mammalian development and stem cell function and are often deregulated in cancers. While the introduction of DNA demethylating agents and HDAC inhibitors in the clinic provides proof-of-concept of the feasibility of targeting the chromatin environment in cancer, and the ongoing development of novel drugs targeting chromatin modifiers show promising results in pre-clinical trials, the mechanisms underlying their efficacy are not understood. Thus, further elucidation of the role of chromatin repressive complexes in cancer and the development of robust predictive biomarkers will be paramount in the implementation of personalized therapies to improve patient outcome.

Acknowledgements

We thank members of the Helin lab for discussions. The work in the Helin lab is supported by grants from the Danish National Research Foundation (DNRF82), the Danish Cancer Society, the Novo Nordisk Foundation, the Danish Council for Strategic Research (12-110503), the Lundbeck Foundation, the European Union and the European Research Council (DNAMET-294666).

References

- Akasaka, T., Kanno, M., Balling, R., Mieza, M.A., Taniguchi, M., and Koseki, H. (1996). A role for mel-18, a Polycomb group-related vertebrate gene, during theanterior-posterior specification of the axial skeleton. *Development* 122, 1513-1522.
- Akasaka, T., van Lohuizen, M., van der Lugt, N., Mizutani-Koseki, Y., Kanno, M., Taniguchi, M., Vidal, M., Alkema, M., Berns, A., and Koseki, H. (2001). Mice doubly deficient for the Polycomb Group genes Mel18 and Bmi1 reveal synergy and requirement for maintenance but not initiation of Hox gene expression. *Development* 128, 1587-1597.
- Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jorgensen, H.F., John, R.M., Gouti, M., Casanova, M., Warnes, G., Merkenschlager, M., *et al.* (2006). Chromatin signatures of pluripotent cell lines. *Nat Cell Biol* 8, 532-538.
- Bantignies, F., Roure, V., Comet, I., Leblanc, B., Schuettengruber, B., Bonnet, J., Tixier, V., Mas, A., and Cavalli, G. (2011). Polycomb-dependent regulatory contacts between distant Hox loci in *Drosophila*. *Cell* 144, 214-226.
- Baubec, T., Ivanek, R., Lienert, F., and Schubeler, D. (2013). Methylation-dependent and -independent genomic targeting principles of the MBD protein family. *Cell* 153, 480-492.

Beguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K.L., Rosen, M., Shen, H., Yang, S.N., Wang, L., Ezponda, T., *et al.* (2013). EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. *Cancer Cell* 23, 677-692.

Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., *et al.* (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* 125, 315-326.

Boyer, L.A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L.A., Lee, T.I., Levine, S.S., Wernig, M., Tajonar, A., Ray, M.K., *et al.* (2006). Polycomb complexes repress developmental regulators in murine embryonic stem cells. *Nature* 441, 349-353.

Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H., and Helin, K. (2006). Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes Dev* 20, 1123-1136.

Bracken, A.P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Monch, K., Minucci, S., Porse, B.T., Marine, J.C., *et al.* (2007). The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. *Genes Dev* 21, 525-530.

Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E., and Helin, K. (2003). EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. *Embo J* 22, 5323-5335.

Brien, G.L., Gambero, G., O'Connell, D.J., Jerman, E., Turner, S.A., Egan, C.M., Dunne, E.J., Jurgens, M.C., Wynne, K., Piao, L., *et al.* (2012). Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. *Nat Struct Mol Biol* 19, 1273-1281.

Buganim, Y., Faddah, D.A., Cheng, A.W., Itskovich, E., Markoulaki, S., Ganz, K., Klemm, S.L., van Oudenaarden, A., and Jaenisch, R. (2012). Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. *Cell* 150, 1209-1222.

Casa, V., and Gabellini, D. (2012). A repetitive elements perspective in Polycomb epigenetics. *Front Genet* 3, 199.

Chamberlain, S.J., Yee, D., and Magnuson, T. (2008). Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. *Stem Cells* 26, 1496-1505.

Chi, A.S., and Bernstein, B.E. (2009). Developmental biology. Pluripotent chromatin state. *Science* 323, 220-221.

Clayton, A.L., Hazzalin, C.A., and Mahadevan, L.C. (2006). Enhanced histone acetylation and transcription: a dynamic perspective. *Mol Cell* 23, 289-296.

Core, N., Bel, S., Gaunt, S.J., Aurrand-Lions, M., Pearce, J., Fisher, A., and Djabali, M. (1997). Altered cellular proliferation and mesoderm patterning in Polycomb-M33-deficient mice. *Development* 124, 721-729.

Cowley, S.M., Iritani, B.M., Mendrysa, S.M., Xu, T., Cheng, P.F., Yada, J., Liggitt, H.D., and Eisenman, R.N. (2005). The mSin3A chromatin-modifying complex is essential for embryogenesis and T-cell development. *Mol Cell Biol* 25, 6990-7004.

da Rocha, S.T., Boeva, V., Escamilla-Del-Arenal, M., Ancelin, K., Granier, C., Matias, N.R., Sanulli, S., Chow, J., Schulz, E., Picard, C., *et al.* (2014). Jarid2 Is Implicated in the Initial Xist-Induced Targeting of PRC2 to the Inactive X Chromosome. *Mol Cell* 53, 301-316.

Dalgliesh, G.L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., *et al.* (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* 463, 360-363.

Dannenberg, J.H., David, G., Zhong, S., van der Torre, J., Wong, W.H., and Depinho, R.A. (2005). mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. *Genes Dev* 19, 1581-1595.

David, G., Grandinetti, K.B., Finnerty, P.M., Simpson, N., Chu, G.C., and Depinho, R.A. (2008). Specific requirement of the chromatin modifier mSin3B in cell cycle exit and cellular differentiation. *Proc Natl Acad Sci U S A* 105, 4168-4172.

David, G., Turner, G.M., Yao, Y., Protopopov, A., and DePinho, R.A. (2003). mSin3-associated protein, mSds3, is essential for pericentric heterochromatin formation and chromosome segregation in mammalian cells. *Genes Dev* 17, 2396-2405.

Davidovich, C., Zheng, L., Goodrich, K.J., and Cech, T.R. (2013). Promiscuous RNA binding by Polycomb repressive complex 2. *Nat Struct Mol Biol* 20, 1250-1257.

de Napoles, M., Mermoud, J.E., Wakao, R., Tang, Y.A., Endoh, M., Appanah, R., Nesterova, T.B., Silva, J., Otte, A.P., Vidal, M., *et al.* (2004). Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. *Dev Cell* 7, 663-676.

del Mar Lorente, M., Marcos-Gutierrez, C., Perez, C., Schoorlemmer, J., Ramirez, A., Magin, T., and Vidal, M. (2000). Loss- and gain-of-function mutations show a polycomb group function for Ring1A in mice. *Development* 127, 5093-5100.

Denisov, S., Hofemeister, H., Marks, H., Kranz, A., Ciotta, G., Singh, S., Anastassiadis, K., Stunnenberg, H.G., and Stewart, A.F. (2014). Mll2 is required for H3K4 trimethylation on bivalent promoters in embryonic stem cells, whereas Mll1 is redundant. *Development* 141, 526-537.

Di Croce, L., and Helin, K. (2013). Transcriptional regulation by Polycomb group proteins. *Nat Struct Mol Biol* 20, 1147-1155.

Donohoe, M.E., Zhang, X., McGinnis, L., Biggers, J., Li, E., and Shi, Y. (1999). Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. *Mol Cell Biol* 19, 7237-7244.

Dovey, O.M., Foster, C.T., and Cowley, S.M. (2010). Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. *Proc Natl Acad Sci U S A* 107, 8242-8247.

Efroni, S., Duttagupta, R., Cheng, J., Dehghani, H., Hoepfner, D.J., Dash, C., Bazett-Jones, D.P., Le Grice, S., McKay, R.D., Buetow, K.H., *et al.* (2008). Global transcription in pluripotent embryonic stem cells. *Cell Stem Cell* 2, 437-447.

Endoh, M., Endo, T.A., Endoh, T., Fujimura, Y., Ohara, O., Toyoda, T., Otte, A.P., Okano, M., Brockdorff, N., Vidal, M., *et al.* (2008). Polycomb group proteins Ring1A/B are functionally linked to the core transcriptional regulatory circuitry to maintain ES cell identity. *Development* 135, 1513-1524.

Endoh, M., Endo, T.A., Endoh, T., Isono, K., Sharif, J., Ohara, O., Toyoda, T., Ito, T., Eskeland, R., Bickmore, W.A., *et al.* (2012). Histone H2A mono-ubiquitination is a crucial step to mediate PRC1-dependent repression of developmental genes to maintain ES cell identity. *PLoS Genet* 8, e1002774.

Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., *et al.* (2010). Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. *Nat Genet* 42, 722-726.

Farcas, A.M., Blackledge, N.P., Sudbery, I., Long, H.K., McGouran, J.F., Rose, N.R., Lee, S., Sims, D., Cerase, A., Sheahan, T.W., *et al.* (2012). KDM2B links the Polycomb Repressive Complex 1 (PRC1) to recognition of CpG islands. *Elife* 1, e00205.

- Faust, C., Lawson, K.A., Schork, N.J., Thiel, B., and Magnuson, T. (1998). The Polycomb-group gene *eed* is required for normal morphogenetic movements during gastrulation in the mouse embryo. *Development* **125**, 4495-4506.
- Faust, C., Schumacher, A., Holdener, B., and Magnuson, T. (1995). The *eed* mutation disrupts anterior mesoderm production in mice. *Development* **121**, 273-285.
- Forzati, F., Federico, A., Pallante, P., Abbate, A., Esposito, F., Malapelle, U., Sepe, R., Palma, G., Troncone, G., Scarfo, M., *et al.* (2012). CBX7 is a tumor suppressor in mice and humans. *J Clin Invest* **122**, 612-623.
- Foster, C.T., Dovey, O.M., Lezina, L., Luo, J.L., Gant, T.W., Barlev, N., Bradley, A., and Cowley, S.M. (2010). Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. *Mol Cell Biol* **30**, 4851-4863.
- Fragola, G., Germain, P.L., Laise, P., Cuomo, A., Blasimme, A., Gross, F., Signaroldi, E., Bucci, G., Sommer, C., Pruneri, G., *et al.* (2013). Cell reprogramming requires silencing of a core subset of polycomb targets. *PLoS Genet* **9**, e1003292.
- Francis, N.J., Kingston, R.E., and Woodcock, C.L. (2004). Chromatin compaction by a polycomb group protein complex. *Science* **306**, 1574-1577.
- Fukuda, T., Tokunaga, A., Sakamoto, R., and Yoshida, N. (2011). Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly. *Mol Cell Neurosci* **46**, 614-624.
- Gao, Z., Zhang, J., Bonasio, R., Strino, F., Sawai, A., Parisi, F., Kluger, Y., and Reinberg, D. (2012). PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. *Mol Cell* **45**, 344-356.
- Guerillon, C., Bigot, N., and Pedoux, R. (2014). The ING tumor suppressor genes: Status in human tumors. *Cancer Lett* **345**, 1-16.
- Hagelkruys, A., Lagger, S., Krahmer, J., Leopoldi, A., Artaker, M., Pusch, O., Zezula, J., Weissmann, S., Xie, Y., Schofer, C., *et al.* (2014). A single allele of Hdac2 but not Hdac1 is sufficient for normal mouse brain development in the absence of its paralog. *Development* **141**, 604-616.
- Harris, W.J., Huang, X., Lynch, J.T., Spencer, G.J., Hitchin, J.R., Li, Y., Ciceri, F., Blaser, J.G., Greystoke, B.F., Jordan, A.M., *et al.* (2012). The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. *Cancer Cell* **21**, 473-487.
- Hayakawa, T., and Nakayama, J. (2011). Physiological roles of class I HDAC complex and histone demethylase. *J Biomed Biotechnol* **2011**, 129383.
- He, X.T., Cao, X.F., Ji, L., Zhu, B., Lv, J., Wang, D.D., Lu, P.H., and Cui, H.G. (2009). Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. *World J Gastroenterol* **15**, 2389-2394.
- Helin, K., and Dhanak, D. (2013). Chromatin proteins and modifications as drug targets. *Nature* **502**, 480-488.
- Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V.A., and Bird, A. (2001). Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. *Genes Dev* **15**, 710-723.
- Hidalgo, I., Herrera-Merchan, A., Ligos, J.M., Carramolino, L., Nunez, J., Martinez, F., Dominguez, O., Torres, M., and Gonzalez, S. (2012). Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. *Cell Stem Cell* **11**, 649-662.
- Hirabayashi, Y., Suzki, N., Tsuboi, M., Endo, T.A., Toyoda, T., Shinga, J., Koseki, H., Vidal, M., and Gotoh, Y. (2009). Polycomb limits the neurogenic competence of neural precursor cells to promote astrogenic fate transition. *Neuron* **63**, 600-613.

Ho, R., Papp, B., Hoffman, J.A., Merrill, B.J., and Plath, K. (2013). Stage-specific regulation of reprogramming to induced pluripotent stem cells by Wnt signaling and T cell factor proteins. *Cell Rep* 3, 2113-2126.

Hu, D., Garruss, A.S., Gao, X., Morgan, M.A., Cook, M., Smith, E.R., and Shilatifard, A. (2013). The Mll2 branch of the COMPASS family regulates bivalent promoters in mouse embryonic stem cells. *Nat Struct Mol Biol* 20, 1093-1097.

Hu, G., and Wade, P.A. (2012). NuRD and pluripotency: a complex balancing act. *Cell Stem Cell* 10, 497-503.

Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., and Melton, D.A. (2008). Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol* 26, 795-797.

Hurst, D.R. (2012). Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes. *Cancer Metastasis Rev* 31, 641-651.

Isono, K., Fujimura, Y., Shinga, J., Yamaki, M., J, O.W., Takihara, Y., Murahashi, Y., Takada, Y., Mizutani-Koseki, Y., and Koseki, H. (2005). Mammalian polyhomeotic homologues Phc2 and Phc1 act in synergy to mediate polycomb repression of Hox genes. *Mol Cell Biol* 25, 6694-6706.

Kadamb, R., Mittal, S., Bansal, N., Batra, H., and Saluja, D. (2013). Sin3: insight into its transcription regulatory functions. *Eur J Cell Biol* 92, 237-246.

Kaji, K., Caballero, I.M., MacLeod, R., Nichols, J., Wilson, V.A., and Hendrich, B. (2006). The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. *Nat Cell Biol* 8, 285-292.

Kaji, K., Nichols, J., and Hendrich, B. (2007). Mbd3, a component of the NuRD co-repressor complex, is required for development of pluripotent cells. *Development* 134, 1123-1132.

Kaneko, S., Bonasio, R., Saldana-Meyer, R., Yoshida, T., Son, J., Nishino, K., Umezawa, A., and Reinberg, D. (2014). Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. *Mol Cell* 53, 290-300.

Kashiwagi, M., Morgan, B.A., and Georgopoulos, K. (2007). The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. *Development* 134, 1571-1582.

Kelly, R.D., and Cowley, S.M. (2013). The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. *Biochem Soc Trans* 41, 741-749.

Kerenyi, M.A., Shao, Z., Hsu, Y.J., Guo, G., Luc, S., O'Brien, K., Fujiwara, Y., Peng, C., Nguyen, M., and Orkin, S.H. (2013). Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. *Elife* 2, e00633.

Khan, O., and La Thangue, N.B. (2012). HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. *Immunol Cell Biol* 90, 85-94.

Kidder, B.L., and Palmer, S. (2012). HDAC1 regulates pluripotency and lineage specific transcriptional networks in embryonic and trophoblast stem cells. *Nucleic Acids Res* 40, 2925-2939.

Kim, W., Bird, G.H., Neff, T., Guo, G., Kerenyi, M.A., Walensky, L.D., and Orkin, S.H. (2013). Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. *Nat Chem Biol* 9, 643-650.

Klauke, K., Radulovic, V., Broekhuis, M., Weersing, E., Zwart, E., Olthof, S., Ritsema, M., Bruggeman, S., Wu, X., Helin, K., *et al.* (2013). Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. *Nat Cell Biol* 15, 353-362.

Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, A.P., Hayes, D.F., *et al.* (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc Natl Acad Sci U S A* *100*, 11606-11611.

Knutson, S.K., Kawano, S., Minoshima, Y., Warholic, N.M., Huang, K.C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., *et al.* (2014). Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 Mutant Non-Hodgkin Lymphoma. *Mol Cancer Ther.*

Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., *et al.* (2013). Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. *Proc Natl Acad Sci U S A* *110*, 7922-7927.

Knutson, S.K., Wigle, T.J., Warholic, N.M., Sneeringer, C.J., Allain, C.J., Klaus, C.R., Sacks, J.D., Raimondi, A., Majer, C.R., Song, J., *et al.* (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. *Nat Chem Biol* *8*, 890-896.

Kohlmaier, A., Savarese, F., Lachner, M., Martens, J., Jenuwein, T., and Wutz, A. (2004). A chromosomal memory triggered by Xist regulates histone methylation in X inactivation. *PLoS Biol* *2*, E171.

Konuma, T., Nakamura, S., Miyagi, S., Negishi, M., Chiba, T., Oguro, H., Yuan, J., Mochizuki-Kashio, M., Ichikawa, H., Miyoshi, H., *et al.* (2011). Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells. *Exp Hematol* *39*, 697-709 e695.

Kooistra, S.M., and Helin, K. (2012). Molecular mechanisms and potential functions of histone demethylases. *Nat Rev Mol Cell Biol* *13*, 297-311.

Kouzarides, T. (2007). Chromatin modifications and their function. *Cell* *128*, 693-705.

Kreso, A., van Galen, P., Pedley, N.M., Lima-Fernandes, E., Frelin, C., Davis, T., Cao, L., Baiazitov, R., Du, W., Sydorenko, N., *et al.* (2014). Self-renewal as a therapeutic target in human colorectal cancer. *Nat Med* *20*, 29-36.

Ku, M., Koche, R.P., Rheinbay, E., Mendenhall, E.M., Endoh, M., Mikkelsen, T.S., Presser, A., Nusbaum, C., Xie, X., Chi, A.S., *et al.* (2008). Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. *PLoS Genet* *4*, e1000242.

Lagarou, A., Mohd-Sarip, A., Moshkin, Y.M., Chalkley, G.E., Bezstarosti, K., Demmers, J.A., and Verrijzer, C.P. (2008). dKDM2 couples histone H2A ubiquitylation to histone H3 demethylation during Polycomb group silencing. *Genes Dev* *22*, 2799-2810.

Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., *et al.* (2002). Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. *Embo J* *21*, 2672-2681.

Lai, A.Y., and Wade, P.A. (2011). Cancer biology and NuRD: a multifaceted chromatin remodelling complex. *Nat Rev Cancer* *11*, 588-596.

Lam, F.H., Steger, D.J., and O'Shea, E.K. (2008). Chromatin decouples promoter threshold from dynamic range. *Nature* *453*, 246-250.

Le Guezennec, X., Vermeulen, M., Brinkman, A.B., Hoeijmakers, W.A., Cohen, A., Lasonder, E., and Stunnenberg, H.G. (2006). MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. *Mol Cell Biol* *26*, 843-851.

Lee, M.G., Wynder, C., Bochar, D.A., Hakimi, M.A., Cooch, N., and Shiekhhattar, R. (2006a). Functional interplay between histone demethylase and deacetylase enzymes. *Mol Cell Biol* *26*, 6395-6402.

Lee, R.S., Stewart, C., Carter, S.L., Ambrogio, L., Cibulskis, K., Sougnez, C., Lawrence, M.S., Auclair, D., Mora, J., Golub, T.R., *et al.* (2012). A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. *J Clin Invest* 122, 2983-2988.

Lee, T.I., Jenner, R.G., Boyer, L.A., Guenther, M.G., Levine, S.S., Kumar, R.M., Chevalier, B., Johnstone, S.E., Cole, M.F., Isono, K., *et al.* (2006b). Control of developmental regulators by Polycomb in human embryonic stem cells. *Cell* 125, 301-313.

Lee, Y., Song, A.J., Baker, R., Micales, B., Conway, S.J., and Lyons, G.E. (2000). Jumonji, a nuclear protein that is necessary for normal heart development. *Circ Res* 86, 932-938.

Leeb, M., Pasini, D., Novatchkova, M., Jaritz, M., Helin, K., and Wutz, A. (2010). Polycomb complexes act redundantly to repress genomic repeats and genes. *Genes Dev* 24, 265-276.

Leeb, M., and Wutz, A. (2007). Ring1B is crucial for the regulation of developmental control genes and PRC1 proteins but not X inactivation in embryonic cells. *J Cell Biol* 178, 219-229.

Liang, G., He, J., and Zhang, Y. (2012). Kdm2b promotes induced pluripotent stem cell generation by facilitating gene activation early in reprogramming. *Nat Cell Biol* 14, 457-466.

Liang, J., Wan, M., Zhang, Y., Gu, P., Xin, H., Jung, S.Y., Qin, J., Wong, J., Cooney, A.J., Liu, D., *et al.* (2008). Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. *Nat Cell Biol* 10, 731-739.

Liu, B., Liu, Y.F., Du, Y.R., Mardaryev, A.N., Yang, W., Chen, H., Xu, Z.M., Xu, C.Q., Zhang, X.R., Botchkarev, V.A., *et al.* (2013). Cbx4 regulates the proliferation of thymic epithelial cells and thymus function. *Development* 140, 780-788.

Lohr, J.G., Stojanov, P., Lawrence, M.S., Auclair, D., Chapuy, B., Sougnez, C., Cruz-Gordillo, P., Knoechel, B., Asmann, Y.W., Slager, S.L., *et al.* (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proc Natl Acad Sci U S A* 109, 3879-3884.

Lu, C., Han, H.D., Mangala, L.S., Ali-Fehmi, R., Newton, C.S., Ozbun, L., Armaiz-Pena, G.N., Hu, W., Stone, R.L., Munkarah, A., *et al.* (2010). Regulation of tumor angiogenesis by EZH2. *Cancer Cell* 18, 185-197.

Luger, K., Rechsteiner, T.J., Flaus, A.J., Waye, M.M., and Richmond, T.J. (1997). Characterization of nucleosome core particles containing histone proteins made in bacteria. *J Mol Biol* 272, 301-311.

Luo, M., Ling, T., Xie, W., Sun, H., Zhou, Y., Zhu, Q., Shen, M., Zong, L., Lyu, G., Zhao, Y., *et al.* (2013). NuRD blocks reprogramming of mouse somatic cells into pluripotent stem cells. *Stem Cells* 31, 1278-1286.

Marchesi, I., Fiorentino, F.P., Rizzolio, F., Giordano, A., and Bagella, L. (2012). The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation. *Cell Cycle* 11, 3828-3836.

Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. *Nature* 469, 343-349.

Marino, S., and Nusse, R. (2007). Mutants in the mouse NuRD/Mi2 component P66alpha are embryonic lethal. *PLoS One* 2, e519.

McCabe, M.T., Graves, A.P., Ganji, G., Diaz, E., Halsey, W.S., Jiang, Y., Smitheman, K.N., Ott, H.M., Pappalardi, M.B., Allen, K.E., *et al.* (2012a). Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). *Proc Natl Acad Sci U S A* 109, 2989-2994.

McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., Liu, Y., Graves, A.P., Della Pietra, A., 3rd, Diaz, E., *et al.* (2012b). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* 492, 108-112.

Mendenhall, E.M., Koche, R.P., Truong, T., Zhou, V.W., Issac, B., Chi, A.S., Ku, M., and Bernstein, B.E. (2010). GC-rich sequence elements recruit PRC2 in mammalian ES cells. *PLoS Genet* 6, e1001244.

Meshorer, E., Yellajoshula, D., George, E., Scambler, P.J., Brown, D.T., and Misteli, T. (2006). Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. *Dev Cell* 10, 105-116.

Metzger, E., Wissmann, M., Yin, N., Muller, J.M., Schneider, R., Peters, A.H., Gunther, T., Buettner, R., and Schule, R. (2005). LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. *Nature* 437, 436-439.

Mikkelsen, T.S., Ku, M., Jaffe, D.B., Issac, B., Lieberman, E., Giannoukos, G., Alvarez, P., Brockman, W., Kim, T.K., Koche, R.P., *et al.* (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature* 448, 553-560.

Mochizuki-Kashio, M., Mishima, Y., Miyagi, S., Negishi, M., Saraya, A., Konuma, T., Shinga, J., Koseki, H., and Iwama, A. (2011). Dependency on the polycomb gene *Ezh2* distinguishes fetal from adult hematopoietic stem cells. *Blood* 118, 6553-6561.

Mohn, F., Weber, M., Rebhan, M., Roloff, T.C., Richter, J., Stadler, M.B., Bibel, M., and Schubeler, D. (2008). Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. *Mol Cell* 30, 755-766.

Mohty, M., Yong, A.S., Szydlo, R.M., Apperley, J.F., and Melo, J.V. (2007). The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. *Blood* 110, 380-383.

Molofsky, A.V., Pardal, R., Iwashita, T., Park, I.K., Clarke, M.F., and Morrison, S.J. (2003). Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. *Nature* 425, 962-967.

Montgomery, N.D., Yee, D., Chen, A., Kalantry, S., Chamberlain, S.J., Otte, A.P., and Magnuson, T. (2005). The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. *Curr Biol* 15, 942-947.

Montgomery, R.L., Davis, C.A., Potthoff, M.J., Haberland, M., Fielitz, J., Qi, X., Hill, J.A., Richardson, J.A., and Olson, E.N. (2007). Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. *Genes Dev* 21, 1790-1802.

Moon, J.H., Heo, J.S., Kim, J.S., Jun, E.K., Lee, J.H., Kim, A., Kim, J., Whang, K.Y., Kang, Y.K., Yeo, S., *et al.* (2011). Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. *Cell Res* 21, 1305-1315.

Morey, L., Pascual, G., Cozzuto, L., Roma, G., Wutz, A., Benitah, S.A., and Di Croce, L. (2012). Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells. *Cell Stem Cell* 10, 47-62.

Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., Paul, J.E., Boyle, M., Woolcock, B.W., Kuchenbauer, F., *et al.* (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet* 42, 181-185.

Motoyama, J., Kitajima, K., Kojima, M., Kondo, S., and Takeuchi, T. (1997). Organogenesis of the liver, thymus and spleen is affected in jumonji mutant mice. *Mech Dev* 66, 27-37.

Muller, J., Hart, C.M., Francis, N.J., Vargas, M.L., Sengupta, A., Wild, B., Miller, E.L., O'Connor, M.B., Kingston, R.E., and Simon, J.A. (2002). Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. *Cell* 111, 197-208.

Nicolson, G.L., Nawa, A., Toh, Y., Taniguchi, S., Nishimori, K., and Moustafa, A. (2003). Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. *Clin Exp Metastasis* 20, 19-24.

Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., *et al.* (2010). Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. *Nat Genet* 42, 665-667.

Nowak, K., Kerl, K., Fehr, D., Kramps, C., Gessner, C., Killmer, K., Samans, B., Berwanger, B., Christiansen, H., and Lutz, W. (2006). BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. *Nucleic Acids Res* 34, 1745-1754.

Ntziachristos, P., Tsirigos, A., Van Vlierberghe, P., Nedjic, J., Trimarchi, T., Flaherty, M.S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., *et al.* (2012). Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. *Nat Med* 18, 298-301.

O'Carroll, D., Erhardt, S., Pagani, M., Barton, S.C., Surani, M.A., and Jenuwein, T. (2001). The polycomb-group gene *Ezh2* is required for early mouse development. *Mol Cell Biol* 21, 4330-4336.

Oguro, H., Yuan, J., Ichikawa, H., Ikawa, T., Yamazaki, S., Kawamoto, H., Nakauchi, H., and Iwama, A. (2010). Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1. *Cell Stem Cell* 6, 279-286.

Ohm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L., Mohammad, H.P., Chen, W., Daniel, V.C., Yu, W., *et al.* (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. *Nat Genet* 39, 237-242.

Onder, T.T., Kara, N., Cherry, A., Sinha, A.U., Zhu, N., Bernt, K.M., Cahan, P., Marcarci, B.O., Unternaehrer, J., Gupta, P.B., *et al.* (2012). Chromatin-modifying enzymes as modulators of reprogramming. *Nature* 483, 598-602.

Orkin, S.H., and Hochedlinger, K. (2011). Chromatin connections to pluripotency and cellular reprogramming. *Cell* 145, 835-850.

Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. *Nature* 423, 302-305.

Pasini, D., Bracken, A.P., Hansen, J.B., Capillo, M., and Helin, K. (2007). The polycomb group protein Suz12 is required for embryonic stem cell differentiation. *Mol Cell Biol* 27, 3769-3779.

Pasini, D., Bracken, A.P., Jensen, M.R., Lazzarini Denchi, E., and Helin, K. (2004). Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. *Embo J* 23, 4061-4071.

Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V.A., Grunn, A., Messina, M., Elliot, O., *et al.* (2011). Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet* 43, 830-837.

Pengelly, A.R., Copur, O., Jackle, H., Herzig, A., and Muller, J. (2013). A histone mutant reproduces the phenotype caused by loss of histone-modifying factor Polycomb. *Science* 339, 698-699.

Pereira, C.F., Piccolo, F.M., Tsubouchi, T., Sauer, S., Ryan, N.K., Bruno, L., Landeira, D., Santos, J., Banito, A., Gil, J., *et al.* (2010). ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency. *Cell Stem Cell* 6, 547-556.

Pirity, M.K., Locker, J., and Schreiber-Agus, N. (2005). Rybp/DEDAF is required for early postimplantation and for central nervous system development. *Mol Cell Biol* 25, 7193-7202.

Puda, A., Milosevic, J.D., Berg, T., Klampfl, T., Harutyunyan, A.S., Gisslinger, B., Rumi, E., Pietra, D., Malcovati, L., Elena, C., *et al.* (2012). Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. *Am J Hematol* 87, 245-250.

Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., *et al.* (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. *Proc Natl Acad Sci U S A* *109*, 21360-21365.

Qin, J., Whyte, W.A., Anderssen, E., Apostolou, E., Chen, H.H., Akbarian, S., Bronson, R.T., Hochedlinger, K., Ramaswamy, S., Young, R.A., *et al.* (2012). The polycomb group protein L3mbtl2 assembles an atypical PRC1-family complex that is essential in pluripotent stem cells and early development. *Cell Stem Cell* *11*, 319-332.

Qureshi, I.A., Gokhan, S., and Mehler, M.F. (2010). REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions. *Cell Cycle* *9*, 4477-4486.

Rais, Y., Zviran, A., Geula, S., Gafni, O., Chomsky, E., Viukov, S., Mansour, A.A., Caspi, I., Krupalnik, V., Zerbib, M., *et al.* (2013). Deterministic direct reprogramming of somatic cells to pluripotency. *Nature* *502*, 65-70.

Reynolds, N., Latos, P., Hynes-Allen, A., Loos, R., Leaford, D., O'Shaughnessy, A., Mosaku, O., Signolet, J., Brennecke, P., Kalkan, T., *et al.* (2012a). NuRD suppresses pluripotency gene expression to promote transcriptional heterogeneity and lineage commitment. *Cell Stem Cell* *10*, 583-594.

Reynolds, N., O'Shaughnessy, A., and Hendrich, B. (2013). Transcriptional repressors: multifaceted regulators of gene expression. *Development* *140*, 505-512.

Reynolds, N., Salmon-Divon, M., Dvinge, H., Hynes-Allen, A., Balasooriya, G., Leaford, D., Behrens, A., Bertone, P., and Hendrich, B. (2012b). NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. *Embo J* *31*, 593-605.

Richly, H., Aloia, L., and Di Croce, L. (2011). Roles of the Polycomb group proteins in stem cells and cancer. *Cell Death Dis* *2*, e204.

Roman-Trufero, M., Mendez-Gomez, H.R., Perez, C., Hijikata, A., Fujimura, Y., Endo, T., Koseki, H., Vicario-Abejon, C., and Vidal, M. (2009). Maintenance of undifferentiated state and self-renewal of embryonic neural stem cells by Polycomb protein Ring1B. *Stem Cells* *27*, 1559-1570.

Ryan, R.J., Nitta, M., Borger, D., Zukerberg, L.R., Ferry, J.A., Harris, N.L., Iafrate, A.J., Bernstein, B.E., Sohani, A.R., and Le, L.P. (2011). EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. *PLoS One* *6*, e28585.

Schenk, T., Chen, W.C., Gollner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.U., Popescu, A.C., Burnett, A., Mills, K., *et al.* (2012). Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. *Nat Med* *18*, 605-611.

Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinooff, B.E., *et al.* (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. *Nat Genet* *39*, 232-236.

Schumacher, A., Faust, C., and Magnuson, T. (1996). Positional cloning of a global regulator of anterior-posterior patterning in mice. *Nature* *384*, 648.

Schwartzentruber, J., Korshunov, A., Liu, X.Y., Jones, D.T., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A.M., Quang, D.A., Tonjes, M., *et al.* (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* *482*, 226-231.

Scott, C.L., Gil, J., Hernando, E., Teruya-Feldstein, J., Narita, M., Martinez, D., Visakorpi, T., Mu, D., Cordon-Cardo, C., Peters, G., *et al.* (2007). Role of the chromobox protein CBX7 in lymphomagenesis. *Proc Natl Acad Sci U S A* *104*, 5389-5394.

Sexton, T., Yaffe, E., Kenigsberg, E., Bantignies, F., Leblanc, B., Hoichman, M., Parrinello, H., Tanay, A., and Cavalli, G. (2012). Three-dimensional folding and functional organization principles of the *Drosophila* genome. *Cell* **148**, 458-472.

Shafaroudi, A.M., Mowla, S.J., Ziaee, S.A., Bahrami, A.R., Atlasi, Y., and Malakootian, M. (2008). Overexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report. *Urol J* **5**, 99-105.

Shen, X., Kim, W., Fujiwara, Y., Simon, M.D., Liu, Y., Mysliwiec, M.R., Yuan, G.C., Lee, Y., and Orkin, S.H. (2009). Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. *Cell* **139**, 1303-1314.

Shen, X., Liu, Y., Hsu, Y.J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G.C., and Orkin, S.H. (2008). EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. *Mol Cell* **32**, 491-502.

Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., and Casero, R.A. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. *Cell* **119**, 941-953.

Shinjo, K., Yamashita, Y., Yamamoto, E., Akatsuka, S., Uno, N., Kamiya, A., Niimi, K., Sakaguchi, Y., Nagasaka, T., Takahashi, T., *et al.* (2013). Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. *Int J Cancer*.

Simhadri, C., Daze, K.D., Douglas, S.F., Quon, T.T., Dev, A., Gignac, M.C., Peng, F., Heller, M., Boulanger, M.J., Wulff, J.E., *et al.* (2014). Chromodomain antagonists that target the polycomb-group methyllysine reader protein Chromobox homolog 7 (CBX7). *J Med Chem*.

Simon, C., Chagraoui, J., Kros, J., Gendron, P., Wilhelm, B., Lemieux, S., Boucher, G., Chagnon, P., Drouin, S., Lambert, R., *et al.* (2012). A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. *Genes Dev* **26**, 651-656.

Su, I.H., Basavaraj, A., Krutchinsky, A.N., Hobert, O., Ullrich, A., Chait, B.T., and Tarakhovsky, A. (2003). Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. *Nat Immunol* **4**, 124-131.

Sun, G., Alzayady, K., Stewart, R., Ye, P., Yang, S., Li, W., and Shi, Y. (2010). Histone demethylase LSD1 regulates neural stem cell proliferation. *Mol Cell Biol* **30**, 1997-2005.

Takawa, M., Masuda, K., Kunizaki, M., Daigo, Y., Takagi, K., Iwai, Y., Cho, H.S., Toyokawa, G., Yamane, Y., Maejima, K., *et al.* (2011). Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. *Cancer Sci* **102**, 1298-1305.

Takeuchi, T., Kojima, M., Nakajima, K., and Kondo, S. (1999). jumonji gene is essential for the neurulation and cardiac development of mouse embryos with a C3H/He background. *Mech Dev* **86**, 29-38.

Takeuchi, T., Yamazaki, Y., Katoh-Fukui, Y., Tsuchiya, R., Kondo, S., Motoyama, J., and Higashinakagawa, T. (1995). Gene trap capture of a novel mouse gene, jumonji, required for neural tube formation. *Genes Dev* **9**, 1211-1222.

Takahara, Y., Tomotsune, D., Shirai, M., Katoh-Fukui, Y., Nishii, K., Motaleb, M.A., Nomura, M., Tsuchiya, R., Fujita, Y., Shibata, Y., *et al.* (1997). Targeted disruption of the mouse homologue of the *Drosophila* polyhomeotic gene leads to altered anteroposterior patterning and neural crest defects. *Development* **124**, 3673-3682.

Tam, W.L., and Weinberg, R.A. (2013). The epigenetics of epithelial-mesenchymal plasticity in cancer. *Nat Med* **19**, 1438-1449.

Tavares, L., Dimitrova, E., Oxley, D., Webster, J., Poot, R., Demmers, J., Bezstarosti, K., Taylor, S., Ura, H., Koide, H., *et al.* (2012). RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. *Cell* **148**, 664-678.

Thillainadesan, G., Chitilian, J.M., Isovici, M., Ablack, J.N., Mymryk, J.S., Tini, M., and Torchia, J. (2012). TGF-beta-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex. *Mol Cell* 46, 636-649.

Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E., and Harte, P.J. (2001). The Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. *Development* 128, 275-286.

Tumes, D.J., Onodera, A., Suzuki, A., Shinoda, K., Endo, Y., Iwamura, C., Hosokawa, H., Koseki, H., Tokoyoda, K., Suzuki, Y., *et al.* (2013). The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. *Immunity* 39, 819-832.

Ueda, T., Sanada, M., Matsui, H., Yamasaki, N., Honda, Z.I., Shih, L.Y., Mori, H., Inaba, T., Ogawa, S., and Honda, H. (2012). EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms. *Leukemia* 26, 2557-2560.

van der Lugt, N.M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te Riele, H., van der Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., *et al.* (1994). Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. *Genes Dev* 8, 757-769.

van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., *et al.* (2009). Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. *Nat Genet* 41, 521-523.

Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, A.P., *et al.* (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature* 419, 624-629.

Versteeg, I., Sevenet, N., Lange, J., Rousseau-Merck, M.F., Ambros, P., Handgretinger, R., Aurias, A., and Delattre, O. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature* 394, 203-206.

Voigt, P., Tee, W.W., and Reinberg, D. (2013). A double take on bivalent promoters. *Genes Dev* 27, 1318-1338.

Voncken, J.W., Roelen, B.A., Roefs, M., de Vries, S., Verhoeven, E., Marino, S., Deschamps, J., and van Lohuizen, M. (2003). Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition. *Proc Natl Acad Sci U S A* 100, 2468-2473.

Wagner, N., Macher-Goeppinger, S., Pritsch, M., Husing, J., Hoppe-Seyler, K., Schirmacher, P., Pfitzenmaier, J., Haferkamp, A., Hoppe-Seyler, F., and Hohenfellner, M. (2010). Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. *BMC Cancer* 10, 524.

Walker, E., Chang, W.Y., Hunkapiller, J., Cagney, G., Garcha, K., Torchia, J., Krogan, N.J., Reiter, J.F., and Stanford, W.L. (2010). Polycomb-like 2 associates with PRC2 and regulates transcriptional networks during mouse embryonic stem cell self-renewal and differentiation. *Cell Stem Cell* 6, 153-166.

Wang, J., Hevi, S., Kurash, J.K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., *et al.* (2009a). The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. *Nat Genet* 41, 125-129.

Wang, J., Scully, K., Zhu, X., Cai, L., Zhang, J., Prefontaine, G.G., Krones, A., Ohgi, K.A., Zhu, P., Garcia-Bassets, I., *et al.* (2007a). Opposing LSD1 complexes function in developmental gene activation and repression programmes. *Nature* 446, 882-887.

Wang, S., He, F., Xiong, W., Gu, S., Liu, H., Zhang, T., Yu, X., and Chen, Y. (2007b). Polycomb-like-2-deficient mice exhibit normal left-right asymmetry. *Dev Dyn* 236, 853-861.

Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., Liang, J., Sun, L., Yang, X., Shi, L., *et al.* (2009b). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. *Cell* 138, 660-672.

Wang, Z., Zang, C., Cui, K., Schones, D.E., Barski, A., Peng, W., and Zhao, K. (2009c). Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. *Cell* 138, 1019-1031.

West, A.C., and Johnstone, R.W. (2014). New and emerging HDAC inhibitors for cancer treatment. *J Clin Invest* 124, 30-39.

Whyte, W.A., Bilodeau, S., Orlando, D.A., Hoke, H.A., Frampton, G.M., Foster, C.T., Cowley, S.M., and Young, R.A. (2012). Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. *Nature* 482, 221-225.

Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D.J., Campan, M., Young, J., Jacobs, I., *et al.* (2007). Epigenetic stem cell signature in cancer. *Nat Genet* 39, 157-158.

Williams, C.J., Naito, T., Arco, P.G., Seavitt, J.R., Cashman, S.M., De Souza, B., Qi, X., Keables, P., Von Andrian, U.H., and Georgopoulos, K. (2004). The chromatin remodeler Mi-2beta is required for CD4 expression and T cell development. *Immunity* 20, 719-733.

Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J., Koellhoffer, E.C., Pomeroy, S.L., Orkin, S.H., and Roberts, C.W. (2010). Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. *Cancer Cell* 18, 316-328.

Winter, M., Moser, M.A., Meunier, D., Fischer, C., Machat, G., Mattes, K., Lichtenberger, B.M., Brunmeir, R., Weissmann, S., Murko, C., *et al.* (2013). Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis. *Embo J* 32, 3176-3191.

Wu, G., Broniscer, A., McEachron, T.A., Lu, C., Paugh, B.S., Becksfort, J., Qu, C., Ding, L., Huether, R., Parker, M., *et al.* (2012). Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat Genet* 44, 251-253.

Wu, X., Johansen, J.V., and Helin, K. (2013). Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation. *Mol Cell* 49, 1134-1146.

Xue, Y., Wong, J., Moreno, G.T., Young, M.K., Cote, J., and Wang, W. (1998). NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. *Mol Cell* 2, 851-861.

Yao, H., Goldman, D.C., Nechiporuk, T., Kawane, S., McWeeney, S.K., Tyner, J.W., Fan, G., Kerenyi, M.A., Orkin, S.H., Fleming, W.H., *et al.* (2014). The co-repressor Rcor1 is essential for murine erythropoiesis. *Blood*.

Yoshida, T., Hazan, I., Zhang, J., Ng, S.Y., Naito, T., Snippert, H.J., Heller, E.J., Qi, X., Lawton, L.N., Williams, C.J., *et al.* (2008). The role of the chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and multilineage differentiation. *Genes Dev* 22, 1174-1189.

You, J.S., and Jones, P.A. (2012). Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell* 22, 9-20.

Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., *et al.* (2012a). The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 481, 157-163.

Zhang, J., Jackson, A.F., Naito, T., Dose, M., Seavitt, J., Liu, F., Heller, E.J., Kashiwagi, M., Yoshida, T., Gounari, F., *et al.* (2012b). Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. *Nat Immunol* 13, 86-94.

Zhang, X.W., Zhang, L., Qin, W., Yao, X.H., Zheng, L.Z., Liu, X., Li, J., and Guo, W.J. (2010). Oncogenic role of the chromobox protein CBX7 in gastric cancer. *J Exp Clin Cancer Res* 29, 114.

Zhao, J., Ohsumi, T.K., Kung, J.T., Ogawa, Y., Grau, D.J., Sarma, K., Song, J.J., Kingston, R.E., Borowsky, M., and Lee, J.T. (2010). Genome-wide identification of polycomb-associated RNAs by RIP-seq. *Mol Cell* 40, 939-953.

Zhao, J., Sun, B.K., Erwin, J.A., Song, J.J., and Lee, J.T. (2008). Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. *Science* 322, 750-756.

Zhu, D., Holz, S., Metzger, E., Pavlovic, M., Jandausch, A., Jilg, C., Galgoczy, P., Herz, C., Moser, M., Metzger, D., *et al.* (2014). Lysine-specific demethylase 1 regulates differentiation onset and migration of trophoblast stem cells. *Nat Commun* 5, 3174.

Zhu, J., Adli, M., Zou, J.Y., Verstappen, G., Coyne, M., Zhang, X., Durham, T., Miri, M., Deshpande, V., De Jager, P.L., *et al.* (2013). Genome-wide chromatin state transitions associated with developmental and environmental cues. *Cell* 152, 642-654.

Tables

Table 1. Loss-of-function phenotypes of Polycomb repressive complexes

	Development	mESCs	Reprogramming	References
PRC1				
<i>Ring1a</i>	Viable with homeotic transformation.		Knockdown impairs reprogramming.	(del Mar Lorente et al., 2000; Onder et al., 2012)
<i>Ring1b</i>	Lethal around E10.5. Gastrulation defects and cell cycle inhibition.	Global loss of H2AK119ub1. Slight deregulation of target genes. Differentiation defects.		(de Napoles et al., 2004; Leeb and Wutz, 2007; Voncken et al., 2003)
<i>Ring1a/Ring1b double KO</i>		Loss H2AK119ub1 (also on Xi), derepression of target genes, loss of self-renewal and differentiation defects.	Knockout impairs reprogramming.	(de Napoles et al., 2004; Endoh et al., 2008; Pereira et al., 2010)
<i>Pcgf2 (Mei18)</i>	Homeotic transformation, postnatal lethality.			(Akasaka et al., 1996)
<i>Pcgf4 (Bmi1)</i>	Homeotic transformation, neurological and immune defects with peri- or postnatal lethality.		Knockdown impairs and overexpression enhances efficiency.	(Moon et al., 2011; Onder et al., 2012; van der Lugt et al., 1994)
<i>Pcgf2/ Pcgf4 double KO</i>	Lethal around E9.5.			(Akasaka et al., 2001)
<i>Cbx2 (M33)</i>	Homeotic transformation and severe immune defects. 50 % die perinatally. Remaining pups die postnatally.			(Core et al., 1997)
<i>Cbx4</i>	Perinatal lethality with severe immune defects.			(Liu et al., 2013)
<i>Cbx7</i>	Increased susceptibility to tumors of liver and lung.			(Forzati et al., 2012)
		Knockdown yields differentiation defects.		(Morey et al., 2012)
<i>Phc1 (Rae28)</i>	Perinatal lethality and homeotic transformation.			(Takahara et al., 1997)
<i>Phc2</i>	Viable with homeotic transformation.			(Isono et al., 2005)
<i>Phc1/2 double KO</i>	Lethal before E11.5.			(Isono et al., 2005)

<i>Rybp</i>	Early postimplantation lethality around E6.5.	Knockdown yields reduction of H2AK119ub1 and differentiation defects.		(Gao et al., 2012; Pirity et al., 2005)
<i>L3mbtl2</i>	Lethal around E9.5. Gastrulation defects.	Decreased proliferation. Differentiation defects.		(Qin et al., 2012)
<i>Kdm2b (Fbxl10)</i>	Incompletely penetrant peri-/postnatal lethality with defects in neural tube closure.	Knockdown yields reduction of H2AK119ub1 and differentiation defects.	Knockdown impairs and overexpression enhances efficiency.	(Fukuda et al., 2011; Liang et al., 2012; Wu et al., 2013)
PRC2				
<i>Ezh2</i>	Lethal around E7.5-8.5. Gastrulation defects.	Global loss of H3K27me2/3, differentiation defects.	Knockout/knockdown impairs reprogramming of human cells. Overexpression enhances, yet knockout does not impair mouse iPSC formation.	(Buganim et al., 2012; Fragola et al., 2013; O'Carroll et al., 2001; Onder et al., 2012; Pereira et al., 2010; Shen et al., 2008)
<i>Ezh1</i>			Not required.	(Onder et al., 2012)
<i>Eed</i>	Lethal around E7.5-8.5. Gastrulation defects.	Global loss of H3K27me2/3, slight derepression of target genes and differentiation defects. Late-passage <i>Eed</i> ^{-/-} cells: Global loss of H3K27me1 and further derepression.	Knockout impairs reprogramming.	(Chamberlain et al., 2008; Faust et al., 1998; Faust et al., 1995; Montgomery et al., 2005; Pereira et al., 2010; Schumacher et al., 1996)
<i>Suz12</i>	Lethal around E7.5-8.5. Gastrulation defects.	Global loss of H3K27me2/3, differentiation defects.	Knockout impairs reprogramming.	(Pasini et al., 2007; Pasini et al., 2004; Pereira et al., 2010)
<i>Jarid2</i>	Lethal at E11.5-15.5 with developmental defects depending on strain.	Differentiation defects.	Not required.	(Lee et al., 2000; Motoyama et al., 1997; Pereira et al., 2010; Shen et al., 2009; Takeuchi et al., 1999; Takeuchi et al., 1995)
<i>Pcl2</i>	Viable with incompletely penetrant defects including homeotic transformations.	Knockdown yields enhanced self-renewal and differentiation defects.		(Walker et al., 2010; Wang et al., 2007b)
<i>Pcl3</i>		Knockdown yields differentiation defects.		(Brien et al., 2012)
<i>Yy1</i>	Peri-implantation lethality.		Knockdown enhances efficiency.	(Donohoe et al., 1999; Onder et al., 2012)

Table 2. Loss-of-function phenotypes of Hdac1/2-containing complexes

	Development	mESCs	Reprogramming	References
Hdac1/2				
<i>Hdac1</i>	Lethal E9.5-10.5.	Decreased proliferation and differentiation defects.		(Dovey et al., 2010; Lagger et al., 2002)
<i>Hdac2</i>	Perinatal lethality with cardiac malformations.	Not effect on self-renewal or pluripotency.		(Dovey et al., 2010; Montgomery et al., 2007)
<i>Hdac1/2</i>			Valproic acid increases efficiency.	(Huangfu et al., 2008)
Sin3				
<i>Sin3a</i>	Periimplantation lethality.	Insufficient outgrowth of ICM during mESC establishment.		(Cowley et al., 2005; Dannenberg et al., 2005)
<i>Sin3b</i>	Perinatal lethality. Pups born in submendelian ratios.			(David et al., 2008)

<i>Sds3</i>	Periimplantation lethality. Defects in chromosome segregation and early lineage specification.		(David et al., 2003)
NuRD			
<i>Mbd2</i>	Mice are viable. Abnormal maternal behavior.		(Hendrich et al., 2001)
<i>Mbd3</i>	Early postimplantation lethality.	Differentiation defects.	Conflicting data: Knockout/knockdown enhances efficiency. Knockout impairs and ectopic expression enhances efficiency. (Hendrich et al., 2001; Kaji et al., 2006; Luo et al., 2013; Rais et al., 2013) (dos Santos et al., 2014, <i>in press</i>)
<i>Gatad2a</i>	Postimplantation lethality, morphological defects.		(Marino and Nusse, 2007)
CoREST			
<i>CoREST</i>	Late embryonic lethality due to severe anemia.		(Yao et al., 2014)
<i>Lsd1</i>	Early embryonic lethality around E5.5 with defects in gastrulation and trophoblast specification.	Reduced CoREST levels, slight deregulation of gene expression and differentiation defects.	(Foster et al., 2010; Wang et al., 2009a; Wang et al., 2007a; Zhu et al., 2014)

Figure legends

Figure 1. Schematic representation of Polycomb repressive complexes.

Polycomb Repressive Complex 2 (PRC2) catalyzes methylation of H3K27 (red circles). Several publications have shown that PRC2 recruitment relies on interacting proteins (such as JARID2, AEBP2 and PCL1-3), transient interactions with cell-type-specific transcription factors or non-coding RNAs. Canonical (CBX-containing) PRC1 complexes are recruited (dashed arrow) to H3K27me3, while Non-canonical (PRC2-independent) PRC1 is recruited (dashed arrow) to CpG islands (blue circles) by KDM2B. Both CBX-containing and PRC2-independent PRC1 complexes catalyze the ubiquitylation of H2AK119 (red hexagons).

Figure 2. Schematic representation of HDAC1/2-containing complexes.

HDAC1/2 of SIN3, NuRD and CoREST catalyze the removal of acetyl groups from histone tails (green triangles). The NuRD subunits CHD3/4 are ATP-dependent chromatin remodelers and LSD1 present in CoREST (and possibly also NuRD) catalyzes demethylation of H3K4me1/2 (green circles). Recruitment of HDAC1/2-containing complexes is thought to rely on chromatin-binding domains within each complex or additional interaction partners (not depicted).

Figure 3. Chromatin sets thresholds for gene activation controlling cell identity.

A. The chromatin environment sets thresholds for gene activation, ensuring that persistent exposure to appropriate signals (e.g. increasing transcription factor levels) is required for transcriptional activation. Loss of chromatin repressive complexes (dashed line) lowers the threshold and increases transcriptional noise. **B.** Changes in chromatin thresholds in turn alter the barriers against changes in cell identity mediated by extrinsic (e.g. growth factors or hormones) and intrinsic (e.g. transcription factor levels or somatic mutations) signals. The biological outcome (whether the barriers are increased or decreased) depends on which genes become aberrantly activated by the loss of chromatin repressive complexes (dashed lines). For instance, if a repressive complex acts to limit the expression of an oncogene, loss of the complex would promote oncogenesis. Conversely, if the complex binds a tumor suppressor, its loss would increase the barrier for oncogenic transformation. Thus, loss of a chromatin repressive complex can influence cell identity in different directions, depending on the genes they regulate and the integration of the combined signals the affected cell receives.

Table 1. Loss-of-function phenotypes of Polycomb repressive complexes.

Table 2. Loss-of-function phenotypes of HDAC1/2-containing complexes.